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Abstract
Multiple Endocrine Neoplasia Type 2 (MEN2) is a rare hereditary complex disorder characterized
by the presence of medullary thyroid carcinoma (MTC), unilateral or bilateral pheochromocytoma
(PHEO) and other hyperplasia and/or neoplasia of different endocrine tissues within a single
patient. MEN2 has been reported in approximately 500 to 1000 families worldwide and the
prevalence has been estimated at approximately 1:30,000. Two different forms, sporadic and
familial, have been described for MEN2. Sporadic form is represented by a case with two of the
principal MEN2-related endocrine tumors. The familial form, which is more frequent and with an
autosomal pattern of inheritance, consists of a MEN2 case with at least one first degree relative
showing one of the characteristic endocrine tumors. Familial medullary thyroid carcinoma (FMTC)
is a subtype of MEN2 in which the affected individuals develop only medullary thyroid carcinoma,
without other clinical manifestations of MEN2. Predisposition to MEN2 is caused by germline
activating mutations of the c-RET proto-oncogene on chromosome 10q11.2. The RET gene encodes
a single-pass transmembrane tyrosine kinase that is the receptor for glial-derived neurotrophic
growth factors. The combination of clinical and genetic investigations, together with the improved
understanding of the molecular and clinical genetics of the syndrome, helps the diagnosis and
treatment of patients. Currently, DNA testing makes possible the early detection of asymptomatic
gene carriers, allowing to identify and treat the neoplastic lesions at an earlier stage. In particular,
the identification of a strong genotype-phenotype correlation in MEN2 syndrome may enable a
more individualized treatment for the patients, improving their quality of life. At present, surgical
treatment offers the only chance of cure and therefore, early clinical and genetic detection and
prophylactic surgery in subjects at risk are the main therapeutic goal.
Definition
Multiple Endocrine Neoplasia Type 2 (MEN2) (OMIM
171400) is a rare hereditary complex disorder character-
ized by the presence of medullary thyroid carcinoma
(MTC), unilateral or bilateral pheochromocytoma
(PHEO) and other hyperplasia and/or neoplasia of differ-
ent endocrine tissues within a single patient. Two different
forms, sporadic and familial, have been described for
MEN2. Sporadic form is represented by a case with two of
the principal MEN2-related endocrine tumors, while the
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familial form, which is more frequent and with an auto-
somal pattern of inheritance, consists of a MEN2 case with
at least one first degree relative showing one of the endo-
crine characterizing tumors.
MEN2 includes three subtypes: MEN2A, MEN2B and
Familial Medullary Thyroid Carcinoma (FMTC).
Epidemiology
MEN2 has been reported in approximately 500 to 1000
families worldwide and the prevalence has been estimated
at approximately 1:30,000. MEN2A accounts for more
than 80% of all MEN2 cases.
Clinical description, diagnostic methods, 
treatments
MEN2A
This variant of the disease is characterized by the presence
of medullary thyroid carcinoma (MTC), unilateral or
bilateral pheochromocytoma (PHEO) (in more than 50%
of cases) and primary hyperparathyroidism (PHPT)
resulting from parathyroid cells hyperplasia or adenoma
(15 to 30% of cases) [1]. Medullary thyroid carcinoma is
generally the first manifestation of MEN2A. In MEN2A
families, the biochemical manifestations of MTC appear
between 5 and 25 years of age [2]. Rare variants of MEN2A
can be associated with paraneoplastic syndromes such as
cutaneous lichen amyloidosis or excessive production of
corticotrophin. The lichenoid skin lesions are usually
located over the upper portion of the back and may
appear before the onset of MTC [3]. In addition, some
patients with MEN2A develop Hirschsprung's disease
(HD) that is characterized by the absence of autonomic
ganglion cells within the distal colonic parasympathetic
plexus, resulting in chronic obstruction and megacolon.
MEN2B
This subtype is the most aggressive MEN2 variant. It
accounts for about 5% of all cases of MEN2. MEN2B is
characterized by the earlier occurrence (usually ten years
earlier than in MEN2A) of a more aggressive MTC, PHEO
(40–50% of cases) and multiple neuromas, and/or diffuse
ganglioneuromatosis of the gastroenteric mucosa (about
40% of cases), but not hyperparathyroidism. Ganglioneu-
romatosis of the gastrointestinal tract is responsible for
abdominal distension, megacolon, constipation or
diarrhea. Patients with MEN2B manifest developmental
abnormalities, such as decreased upper/lower body ratio,
skeletal deformations (kyphoscoliosis or lordosis), joint
laxity, marfanoid habitus and myelinated corneal nerves.
Morbidity and mortality is higher in patients with MEN2B
than in patients with MEN2A.
Familial Medullary Thyroid Carcinoma (FMTC)
In FMTC, MTC is the only clinical feature. This form,
according to the statement of the International RET Muta-
tion Consortium [4], refers to the occurrence of MTC only
in at least four affected members within the same family.
In FMTC, the clinical course of MTC is more benign than
that in MEN2A and MEN2B, and the prognosis is rela-
tively good in most cases [5].
Medullary Thyroid Carcinoma (MTC)
This tumor, originating from the parafollicular calcitonin-
producing cells (C-cells), is the first clinical manifestation
in most MEN2 kindreds and occurs in all MEN2 patients.
MTC usually occurs in a decreasing order of severity in
MEN2B, MEN2A and FMTC, respectively [6]. MTC origi-
nates as multifocal C-cell hyperplasia, whose progression
to MTC is extremely variable and may take several years
[7]. MTC exhibits a natural tendency to local metastases
(central and lateral, cervical and mediastinal lymph
nodes) and, often, to distant lesions (liver, bones and
lungs) [8].
In MEN2A patients, the biochemical manifestations of
MTC generally appear between the age of 5 and 25 years.
If these individuals are untreated, MTC can manifest as a
neck mass or neck pain at age of 15 to 20 years. Diarrhea
may occur in patients with spread metastases from MTC,
in association with high plasma calcitonin concentra-
tions.
In MEN2B patients, the MTC is more aggressive and usu-
ally develops about a decade earlier. Individuals with
MEN2B who do not undergo thyroidectomy at age of one
year, are likely to develop metastatic MTC at early age.
MTC generally correlates with increased circulating levels
of calcitonin (basal, or stimulated by pentagastrin and cal-
cium, or both), thus calcitonin can be considered as a spe-
cific tumor marker for MTC (normal basal value <10 pg/
ml). In the 1970s, the introduction of specific tests to eval-
uate calcitonin secretion under stimulation with penta-
gastrin or calcium enhanced the possibility for earlier
detection of MTC [9]. Similarly, an elevated calcitonin
serum level after surgery can be a sign of persistent, recur-
rent or generalized MTC [5,10].
Surgery is the treatment of choice for MTC, in both
MEN2A and MEN2B patients. It consists of total thyroid-
ectomy and lymph node dissection of at least the central
compartment, that should ideally be performed before
the age of possible malignant progression. Fine-needle
biopsy and evaluation of serum calcitonin level (basal,
and two and five minutes after stimulation with calcium)
have been shown to help the preoperative diagnosis of
MTC. Calcitonin stimulation test can be useful for presur-Orphanet Journal of Rare Diseases 2006, 1:45 http://www.OJRD.com/content/1/1/45
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gical assessment of MTC stage, as there is a positive corre-
lation between basal and stimulated calcitonin levels, and
Tumor-Nodes-Metastasis (TNM) classification. Moreover,
imaging procedures, such as ultrasonography, computed
tomography (CT) or magnetic resonance imaging (MRI)
may be used to determine tumor's extension and possible
distant metastases [11].
Pheochromocytoma (PHEO)
This catecholamine-producing tumor of the adrenal gland
appears in about 50% of the MEN2A and MEN2B
patients. Pheochromocytomas in MEN2 are almost
always benign but tend to be bilateral in 50–80% of cases.
Generally, PHEO is the first clinical manifestation of the
disease in 25% of cases (after MTC in 40%); in 35% of
cases, MTC and PHEO are diagnosed at the same time
[5,12-14]. PHEO may account for hypertension, episodic
headache, palpitations, nervousness, sweating and
blanching of the skin due to excessive synthesis of epine-
phrine, norepinephrine and dopamine by the chromaffin
cells of the adrenal gland. Prior to surgery, the presence of
a functioning PHEO should be excluded by appropriate
biochemical analysis in all MEN2A and MEN2B individu-
als. If PHEO is detected, adrenalectomy should be per-
formed before thyroidectomy or any other surgical
intervention, in order to avoid intraoperative catecho-
lamine crisis. Adrenal gland function can be easily
assessed by 24 hours measurements of urinary excretion
of catecholamines and their metabolites (norepinephrine,
epinephrine, metanephrine and vanillymandelic acid
(VMA)); this screening is recommended on an annual
basis. Once the biochemical diagnosis of PHEO has been
made, CT and MRI can be used to localize the tumor, with
a specificity of about 70%. 123I-meta-iodobenylguanidine
scintigraphy (iodine-123-MIGB) of the whole body is
helpful in patients with suspected multifocal or extra-
adrenal PHEO, with a sensitivity of about 80% and a spe-
cificity of nearly 100%. The treatment of PHEO is surgical
laparoscopy excision. Life-long follow-up after surgery is
strongly recommended. Long-term drug treatment with α
and β adrenergic blockers should be considered only in
patients with unresectable (for various reasons) tumor.
Primary Hyperparathyroidism (PHPT)
PHPT occurs in 20 to 30% of MEN2A patients and is
asymptomatic in most cases (6). The diagnosis is made by
biochemical screening showing an elevated serum parath-
yroid hormone (PTH) and calcium concentrations. Treat-
ment of PHPT in MEN2 is surgical, by subtotal
parathyroidectomy or total parathyroidectomy with
autotransplantation of normal fresh or cryopreserved tis-
sue in the sternocleidoid muscle or in the forearm [5]. All
individuals who have undergone subtotal parathyroidec-
tomy or total parathyroidectomy with autotransplanta-
tion need to be monitored for possible recurrences.
Molecular genetics of MEN2
c-RET oncogene and its protein
In 1993, MEN2 syndrome was strongly associated with
activating mutations of the c-RET  proto-oncogene
[15,16]. This gene is located on the pericentromeric
region of chromosome 10 (10q12.2). It has twenty-one
exons and encodes a membrane tyrosine kinase receptor
protein named RET. The RET protein is a subunit of a mul-
timolecular complex that binds growth factors of the glial
derived neurotrophic factor (GDNF) family. It consists of
i) an extracellular portion composed by six different
domains (four cadherine-like domains, a calcium-bind-
ing site and a cysteine-rich domain), ii) a single-pass
transmembrane domain and iii) an intracellular portion
containing two distinct tyrosine kinase domains. The
intracellular domain of RET contains at least 12 autophos-
phorylation sites. RET phosphorylated tyrosines serve as
docking sites for intracellular signaling proteins.
Approximately 98% of MEN2 patients bear germline
mutations of c-RET [6]. MEN2 mutations are localized in
exons 10, 11, 13, 14, 15 and 16. Very recently, mutations
in exon 8 have been found in a FMTC family [17]. Muta-
tions of c-RET in the cysteine-rich domain and in the tyro-
sine kinase domains result all in a constitutive tyrosine
kinase activation of the mutant receptor.
Genotype-phenotype correlation
MEN2 syndrome exhibits a strong genotype-phenotype
correlation. Missense mutations at one of six cysteines in
the extracellular cysteine-rich domain of RET (609, 611,
618, 620, 630 at exon 10 and 634 at exon 11) are respon-
sible for the majority of cases of MEN2A (93–98%) and a
majority of FMTC (80–96%). Eighty-five percent of
MEN2A patients have a codon 634 mutation, particularly
C634R, strictly associated with the occurrence of PHEO
and/or primary hyperparathyroidism [18]. Only 30% of
FMTC patients have a codon 634 mutations; in general,
the mutations in FMTC patients are distributed among the
six cysteine codons. FMTC and rare cases of MEN2A have
been also associated with missense mutations in the intra-
cellular domain of RET, such as codons 768, 790 and 791
at exon 13, codons 804 and 844 at exon 14 and codon
891 at exon 15 [19].
Rare mutations in codon 631 at exon 10 have also been
found in FMTC. In contrast, most of MEN2B cases are
associated with mutations in the intracellular tyrosine
kinase receptor domains of RET: more than 95% of
MEN2B patients bear the M918T mutation at exon 16,
while about 5% of MEN2B patients harbor the A883F sub-
stitution at exon 15 [20,21].Orphanet Journal of Rare Diseases 2006, 1:45 http://www.OJRD.com/content/1/1/45
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Recently, other infrequent missense mutations at exons
14, 15 and 16 (respectively at codons 804 and 806, 904,
and 922) have been found in MEN2B patients [11].
The oncogenic mechanisms of different RET mutations
seem to be dependent on the site of the amino acid
change. Cysteine substitution with several other residues,
in the cysteine-rich domain, is believed to prevent the for-
mation of intramolecular disulfide bonds, enabling lig-
and-independent receptor dimerization and resulting in a
constitutive kinase activation. Thus, cysteine point muta-
tions of MEN2A and FMTC have a "gain of function"
effect on RET. When triggered by its ligand, wild type RET
receptors are induced to dimerize and this dimerization
activates RET kinase activity and signal transduction [22].
In MEN2A and FMTC, mutated RET receptors, as a conse-
quence of substitution of one extracellular cysteine resi-
due, are constitutively dimerized independently of ligand.
Mutations at cysteine 634 have shown a stronger trans-
forming ability than mutations at other extracellular
cysteines. In contrast, the great majority of mutations in
MEN2B cases affect one of two intracellular tyrosine
kinase domains. However, little is known at present about
the mechanisms of RET activation by mutations in the
tyrosine kinase domains. RET phosphorylated tyrosines
interact with the docking protein FSR2 causing the down-
stream activation of the mitogen-activated protein kinase
(MAPK) signaling cascade [23]. Thus, mutations at this
level may determinate an alteration of the regulation of
MAPK pathways [24,25]. Recently, a microarray expres-
sion analysis of PHEO and MTC tissues from patients with
MEN2A and MEN2B demonstrated different gene expres-
sion profiles, possibly explaining the more aggressive
nature of MEN2B [26].
Genetic screening and management
MTC represents the first clinical manifestation of MEN2
syndrome and is the principal cause of morbidity and
mortality. Early identification of MTC, mostly in MEN2B
patients, is important because of its tendency to metasta-
size in early age. In 1970s, the development of specific
tests to evaluate calcium or pentagastrin-stimulating
release of calcitonin allowed the detection of MTC in its
earliest stage [9]. Nevertheless, it was the discovery of the
correlation between mutations of c-RET and MEN2 syn-
drome in 1993 that has opened a new era in the early rec-
ognition and clinical management of the affected and at-
risk individuals. The DNA-based testing of the c-RET gene
can be easily performed on a blood sample at any age. It
offers the opportunity for early identification of the c-RET
germline mutations, thus contributing to the reduction of
morbidity and mortality of MEN2 syndrome. In fact, the
early recognition of the mutant gene carriers makes possi-
ble the prevention and cure of MTC, by performing a pro-
phylactic thyroidectomy before the clinical expression of
the tumor. This test is also of importance to detect and
thus, to reduce the risk of an unsuspected PHEO. Moreo-
ver, the aggressiveness of MTC correlates with the specific
c-RET codon mutation and this strong genotype-pheno-
type correlation ulteriorly contributes to the clinical man-
agement of patients. Specific c-RET mutations, in fact, are
associated to peculiar clinical phenotypes and thus to dif-
ferent course and prognosis of the disease. During the Sev-
enth International Multiple Endocrine Neoplasia Meeting
in Gubbio in 1999 [6], the risk of MTC has been stratified
in three categories according to the mutations of c-RET:
1) Children with MEN2B and/or c-RET codon 883, 918,
922 mutations have the highest risk of aggressive MTC
(level 3) and should undergo a total thyroidectomy with
central node dissection, within the first six months.
2) Children with any c-RET codon 611, 618, 620 or 634
mutations have a high risk of MTC (level 2); in this case,
a total thyroidectomy should be performed before age of
five years, with or without central node dissection.
3) Children with c-RET codon 609, 768, 790, 791, 804
and 891 mutations have a less aggressive and slowly grow-
ing MTC (level 1) and may be operated at a later stage.
Some clinicians recommend a prophylactic thyroidec-
tomy by the age of five, while others suggest thyroidec-
tomy by age of ten. A periodic pentagastrin-stimulated test
with thyroidectomy, at the first abnormal test result, has
also been proposed.
Nevertheless, for all three groups, a more aggressive neck
dissection should be performed if there is an evidence of
lateral lymph nodes involvement [27]. For individuals
bearing other c-RET known mutations, no specific recom-
mendations can be made at present, as there is no suffi-
cient experience with these kindreds. More recently,
Cohen and Moley have suggested a prophylactic thyroid-
ectomy with autotransplantation of parathyroids as a pri-
mary preventive measure for all individuals with
identified germline c-RET mutation [28].
Genetic information can also be useful to assess the risk of
developing PHEO. Individuals with c-RET  codon 609,
611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922
mutations should be routinely screened for PHEO by
annual determinations of fractionated urinary and free
plasma metanephrines and catecholamines. In contrast, it
is reasonably acceptable that development of PHEO is
unlikely in patients with codon 768 and V804M muta-
tions [29].
Genetic counseling
MEN2 is a monogenic disorder and, according to its auto-
somal dominant pattern of inheritance, each affectedOrphanet Journal of Rare Diseases 2006, 1:45 http://www.OJRD.com/content/1/1/45
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individual has a 50% probability of transmitting the gene
defect to progeny, independently by sex.
Prognosis
MEN2 is a rare hereditary cancer disease expressing a vari-
ety of aggressive endocrine and non-endocrine tumors.
Although uncommon, this syndrome is important to be
early recognized because the gene mutations confer a high
risk of multiple aggressive primary tumors occurring at
very young ages. Medullary thyroid carcinoma occurs in
all patients with MEN2 and it can be lethal. In 1993, the
discovery of MEN2 responsible gene strengthened the
possibility of early identification of the affected and at-
risk individuals. In the last decades, the increasing knowl-
edge on the molecular and clinical features of MEN2 syn-
drome, together with the availability of genetic tests,
greatly increased the opportunities of intervention and,
consequently, lead to reduced morbidity and mortality. At
the moment, surgical treatment offers the only chance of
cure and therefore early clinical and genetic detection and
prophylactic surgery are the goal in subjects at risk.
Perspectives
Further studies on the molecular pathways of c-RET gene
and its protein will help to design novel and more indi-
vidualized therapeutic modalities based on genetic infor-
mation [30]. In fact, although the knowledge about
mechanisms of tumor development in patients with
MEN2 has grown tremendously, much work lies ahead.
The final goal is to offer patients with c-RET  germline
mutations an optimal cancer prevention and treatment
program.
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